ArticleEcancermedicalscience2025
Primary treated versus referred trunk and extremities soft tissue sarcomas: comparative analysis of initial treatment impact on disease control.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Soft tissue sarcomas (STS) are rare and aggressive tumours that require a complex multimodal treatment at referral centers. However, they are often misdiagnosed and subsequently improperly treated at non-specialised centers. A multidisciplinary approach is mandatory for these tumours, involving multiple specialties. Therefore, management should be carried out in reference centers for STS. We aimed to compare oncological outcomes of trunk and extremities STS primarily treated at a reference center versus those referred after initial surgical treatment elsewhere. Methods: All patients with diagnosis of trunk and extremities STS between January 2010 and May 2024, primarily operated at our center or referred after treatment elsewhere, were included. Visceral, retroperitoneal/pelvic, spermatic cord and head/neck STS were excluded, as well as desmoid tumours and dermatofibrosarcoma protuberans subtype. Demographic data and tumour characteristics were evaluated (location, size, French Federation of Cancer Centers Sarcoma Group grade, neo/adjuvant treatment) as well as primary surgery outcomes (R classification). The cohort was divided into two groups: G1 (primary-resection group) and G2 (referred group). Overall survival (OS), local recurrence-local relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were compared between groups. Results: A total of 102 trunk and extremities STS underwent surgical resection on the mentioned period, out of which 49 were primarily resected (G1) and 53 had previous resections elsewhere (G2: 33 referred for recurrent tumours and 20 referred after inadequate excision). Data on grade was available for 91 lesions and 67% (61/91) were high-grade, with no significant differences between groups. The two groups had statistically significant differences in median tumour size (G1: 9.5 cm versus G2: 4 cm; Conclusion: Better local control was achieved in patients initially treated at our center. Being surgical margin status is the primary prognostic factor for LRFS, STS should be treated in referral centers where a multidisciplinary approach and proper oncologic resections following sarcomas guidelines recommendations are standard of care. Hence, the importance of a prompt referral even before any intervention in the event of a suspected diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.